Quick Answer
NeuroSense Therapeutics Ltd. reported Net Income of -$11.12 million for fiscal year 2025.
NeuroSense Therapeutics Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$11.12M -9.0% |
-$10.21M -1.0% |
-$10.11M +3.7% |
-$10.49M | — | — |
| Diluted EPS | -$0.44 +18.5% |
-$0.54 +27.0% |
-$0.74 +18.7% |
-$0.91 | — | — |
| Total Assets | $1.03M -77.5% |
$4.58M +43.6% |
$3.19M -58.7% |
$7.71M -32.6% |
$11.43M +1367.4% |
$779.0K |
| Cash and Equivalents | $166.0K -95.1% |
$3.38M +28.0% |
$2.64M | — | — | — |
| Stockholders Equity | -$1.56M -160.4% |
$2.58M +246.8% |
-$1.76M -130.1% |
$5.84M -46.1% |
$10.83M | — |
| R&D Expense | $6.23M +9.3% |
$5.70M -21.7% |
$7.27M +30.2% |
$5.59M | — | — |
| Operating Income | -$11.09M -11.9% |
-$9.90M +17.8% |
-$12.05M -14.2% |
-$10.55M | — | — |
| Shares Outstanding | 32.56M +40.2% |
23.23M +51.0% |
15.38M | — | — | — |
- NeuroSense Therapeutics Ltd. reported Net Income of -$11.12 million for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed a decrease of -9.0% in Net Income compared to the prior fiscal year.
- NeuroSense Therapeutics Ltd. reported Diluted EPS of $0.44 per share (loss) for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed an increase of +18.5% in Diluted EPS compared to the prior fiscal year.
- NeuroSense Therapeutics Ltd. reported Total Assets of $1.03 million for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed a decrease of -77.5% in Total Assets compared to the prior fiscal year.
- NeuroSense Therapeutics Ltd. reported Cash and Equivalents of $166.0 thousand for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed a decrease of -95.1% in Cash and Equivalents compared to the prior fiscal year.
- NeuroSense Therapeutics Ltd. reported Stockholders Equity of -$1.56 million for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed a decrease of -160.4% in Stockholders Equity compared to the prior fiscal year.
- NeuroSense Therapeutics Ltd. reported R&D Expense of $6.23 million for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed an increase of +9.3% in R&D Expense compared to the prior fiscal year.
- NeuroSense Therapeutics Ltd. reported Operating Income of -$11.09 million for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed a decrease of -11.9% in Operating Income compared to the prior fiscal year.
- NeuroSense Therapeutics Ltd. reported Shares Outstanding of 32.56 million shares for fiscal year 2025.
- NeuroSense Therapeutics Ltd. showed an increase of +40.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: